Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 6
2005 5
2006 11
2007 10
2008 12
2009 15
2010 9
2011 12
2012 18
2013 22
2014 27
2015 25
2016 24
2017 16
2018 12
2019 21
2020 30
2021 21
2022 28
2023 26
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean noriko katoh (4 results)?
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Reich K, et al. Among authors: katoh n. Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0. Lancet. 2022. PMID: 35871814 Clinical Trial.
Japanese guidelines for atopic dermatitis 2020.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Katoh N, et al. Allergol Int. 2020 Jul;69(3):356-369. doi: 10.1016/j.alit.2020.02.006. Epub 2020 Apr 4. Allergol Int. 2020. PMID: 32265116 Free article. Review.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Simpson EL, et al. N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30. N Engl J Med. 2016. PMID: 27690741 Free article. Clinical Trial.
Enhanced early skin treatment for atopic dermatitis in infants reduces food allergy.
Yamamoto-Hanada K, Kobayashi T, Mikami M, Williams HC, Saito H, Saito-Abe M, Sato M, Irahara M, Miyaji Y, Ishikawa F, Tsuchiya K, Tamagawa-Mineoka R, Takaoka Y, Takemura Y, Sato S, Wakiguchi H, Hoshi M, Natsume O, Yamaide F, Seike M, Ohya Y; PACI Study Collaborators. Yamamoto-Hanada K, et al. J Allergy Clin Immunol. 2023 Jul;152(1):126-135. doi: 10.1016/j.jaci.2023.03.008. Epub 2023 Mar 22. J Allergy Clin Immunol. 2023. PMID: 36963619 Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies.
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, Hercogová J, Hong CH, Katoh N, Pink AE, Richard MA, Shumack S, Silvestre JF, Weidinger S. De Bruin-Weller M, et al. Among authors: katoh n. Acta Derm Venereol. 2021 Feb 17;101(2):adv00402. doi: 10.2340/00015555-3751. Acta Derm Venereol. 2021. PMID: 33491094 Free PMC article.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Guttman-Yassky E, et al. Among authors: katoh n. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Lancet. 2021. PMID: 34023008 Clinical Trial.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Simpson EL, et al. Among authors: katoh n. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. JAMA Dermatol. 2022. PMID: 35262646 Free PMC article.
302 results